Immutep (ASX:IMM) ended the fiscal third quarter with a cash balance of AU$92.5 million, according to a Tuesday filing with the Australian bourse.

It also has short-term bank deposits of AU$53.8 million, the filing said.

The clinical-stage biotechnology company saw progress in its ongoing trials during the quarter. This year, it expects analysis and safety assessment reports for treatments of breast cancer and autoimmune disease.